Chimerix Raises $23.1 Million

Chimerix Inc., a Seattle-based developer of orally-available antiviral therapeutics, has raised $23.1 million in Series D funding. Canaan Partners led the deal, and was joined by Alta Partners and return backers Sanderling Ventures, Asset Management Company and Frazier Healthcare Ventures. www.chimerix.com